A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis

Overview of attention for article published in American Journal of Gastroenterology, August 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 7 news outlets

twitter: 16 X users

Readers on

mendeley: 23 Mendeley

So far, Altmetric has seen 7 news stories from 7 outlets.

American Journal of Gastroenterology Publishes Data from HighTide Therapeutics' Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis

Yahoo! Finance USA, 20 Nov 2022

ROCKVILLE, MD and SHENZHEN, CHINA - () - November 20, 2022 - HighTide Therapeutics, Inc.

American Journal of Gastroenterology Publishes Data from HighTide Therapeutics' Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis

Biz Wire Express, 17 Nov 2022

ACN Newswire 2022-11-16 ROCKVILLE, MD and SHENZHEN, CHINA, Nov 16, 2022 - (ACN Newswire) - HighTide Therapeutics, Inc.

AJG Publishes Data from HighTide Therapeutics’ Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis

Intellasia, 17 Nov 2022

- (ACN Newswire) - HighTide Therapeutics, Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company…

AJG Publishes Data from HighTide Therapeutics' Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis

JCN Newswire, 17 Nov 2022

- (ACN Newswire) - HighTide Therapeutics, Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 3 additional news stories.